Home  »  Industry   »  Which Institutions Own Shares In Karyopharm Therap...

Which Institutions Own Shares In Karyopharm Therapeutics Inc. (KPTI)?

Karyopharm Therapeutics Inc. (NASDAQ: KPTI) is -26.47% lower on its value in year-to-date trading and has touched a low of $2.28 and a high of $6.84 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The KPTI stock was last observed hovering at around $2.59 in the last trading session, with the day’s loss setting it -0.09% off its average median price target of $7.50 for the next 12 months. It is also 75.0% off the consensus price target high of $10.00 offered by 10 analysts, but current levels are 50.0% higher than the price target low of $5.00 for the same period.

Currently trading at $2.50, the stock is -12.80% and -27.03% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 2.69 million and changing -3.47% at the moment leaves the stock -38.93% off its SMA200. KPTI registered -57.12% loss for a year compared to 6-month loss of -46.92%. The firm has a 50-day simple moving average (SMA 50) of $1.53 and a 200-day simple moving average (SMA200) of -$1.71.

Top 5 EV Tech Stocks to Buy for 2023

According a new report published by BloombergNEF on investment in the energy transition, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now.

Click Here to Download the FREE Report.


The stock witnessed a -33.33% gain in the last 1 month and extending the period to 3 months gives it a -21.38%, and is 2.04% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 6.10% over the week and 9.21% over the month.

Karyopharm Therapeutics Inc. (KPTI) has around 385 employees, a market worth around $280.40M and $148.10M in sales. Distance from 52-week low is 9.65% and -63.45% from its 52-week high. The company has generated returns on investments over the last 12 months (-49.80%).

Karyopharm Therapeutics Inc. (KPTI) Analyst Forecasts

Analyst recommendations provided by FactSet shows that the consensus forecast for Karyopharm Therapeutics Inc. (KPTI) is a “Overweight”. 10 analysts offering their recommendations for the stock have an average rating of 2.20, where 4 rate it as a Hold and 2 think it is a “Overweight”. 4 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.

The EPS is expected to shrink by -22.40% this year

Karyopharm Therapeutics Inc. (KPTI) Top Institutional Holders

The shares outstanding are 113.48M, and float is at 74.06M with Short Float at 24.25%.

Karyopharm Therapeutics Inc. (KPTI) Insider Activity

A total of 22 insider transactions have happened at Karyopharm Therapeutics Inc. (KPTI) in the last six months, with sales accounting for 15 and purchases happening 7 times. The most recent transaction is an insider sale by Paulson Richard A., the company’s President and CEO. SEC filings show that Paulson Richard A. sold 3,805 shares of the company’s common stock on May 04 at a price of $3.35 per share for a total of $12753.0. Following the sale, the insider now owns 0.81 million shares.

Karyopharm Therapeutics Inc. disclosed in a document filed with the SEC on Apr 20 that Rangwala Reshma (EVP & Chief Medical Officer) sold a total of 6,770 shares of the company’s common stock. The trade occurred on Apr 20 and was made at $4.05 per share for $27416.0. Following the transaction, the insider now directly holds 0.16 million shares of the KPTI stock.

Still, SEC filings show that on Apr 04, Paulson Richard A. (President and CEO) disposed off 3,497 shares at an average price of $3.97 for $13883.0. The insider now directly holds 816,619 shares of Karyopharm Therapeutics Inc. (KPTI).

Karyopharm Therapeutics Inc. (KPTI): Who are the competitors?

The company’s main competitors (and peers) include Bristol-Myers Squibb Company (BMY) that is trading -14.64% down over the past 12 months and Abbott Laboratories (ABT) that is -9.55% lower over the same period. Exelixis Inc. (EXEL) is 8.87% up on the 1-year trading charts.

Most Popular

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Related Posts